Clinical Research

ACEMg for GJB2 / Connexin 26 Progressive Hearing Loss

Supporting prospective clinical observation in pediatric hereditary hearing loss

Available for clinical research and clinical use

For children with confirmed GJB2 mutations and documented audiometric progression, there is currently no pharmacological or nutritional intervention embedded in standard audiological or otolaryngological guidelines. Families are counseled to monitor and wait, with cochlear implantation as the endpoint of escalation.

Two peer-reviewed publications suggest that ACEMg supplementation, the first evidence-based formulation in the emerging field of auditory micronutrition (a precise combination of beta-carotene, vitamins C and E, and magnesium), may support cochlear health and slow hearing threshold deterioration in this specific genetic context. The published evidence warrants systematic prospective observation. We are actively seeking clinicians willing to track audiometric outcomes in children with GJB2 mutations who elect supplementation.

An Unmet Clinical Need

Parents of children with GJB2-related progressive hearing loss are regularly discovering this literature on their own, without the guidance of their clinical teams. In our experience, and in the experience documented in our recently submitted case report, the pattern is consistent across audiology, ENT, and genetics providers: the published evidence on ACEMg and GJB2 is not reaching the clinicians who care for these children.

A mother whose daughter had documented audiometric progression of 15 to 30 dB over five years, confirmed compound heterozygous GJB2 mutations, and no offered intervention from any provider, independently located the ACEMg literature on PubMed. Her geneticist attributed the progression to improvements in pure-tone test-taking ability. Her first ENT refused genetic testing on the grounds that it would not change the plan of care. Her second ENT, receptive and informed, had not encountered the ACEMg literature. None of this represents individual clinician failure. It represents a knowledge gap with direct clinical consequences for an identifiable, growing patient population.

Important: ACEMg Is Not Appropriate for All Forms of Genetic Hearing Loss

A 2016 preclinical study (Green et al.) found that ACEMg worsened hearing outcomes in a mouse model of DIAPH3 (AUNA1)-related hereditary deafness. The authors concluded that antioxidant supplementation can have mutation-specific effects, beneficial or detrimental, depending on the underlying cochlear pathophysiology.

Genetic diagnosis confirming GJB2 mutations must precede any clinical consideration of ACEMg. This formulation is not a universal hearing supplement. Its rationale applies specifically to mutations involving cochlear oxidative stress, of which GJB2 is the most prevalent example.

Mechanism of Action

Counteracts Cochlear Oxidative Stress

Gap junctions containing Connexin 26 normally facilitate potassium recycling in the cochlear epithelium. When Cx26 is absent or dysfunctional, potassium accumulates in the extracellular space surrounding hair cells, generating reactive oxygen species through a cascade chemically similar to noise-induced cochlear damage. ACEMg is formulated to reduce this oxidative load in cochlear supporting cells and hair cells.

Supports Gap Junction Function

Published research demonstrates that antioxidants can preserve gap junction function. In cases of partial rather than complete loss-of-function GJB2 mutations, residual Cx26 protein activity may itself benefit from reduced oxidative stress in the pericochlear environment.

Well-Characterized Safety Profile

The individual components of ACEMg, beta-carotene, vitamins C and E, and magnesium, are the subject of extensive safety literature. The 2014 case report documented three years of supplementation at doses within US Institute of Medicine tolerable upper intake levels for pediatric patients, with no adverse effects.

Published Evidence

Case Report, 2014

Thatcher and colleagues reported a child compound heterozygous for GJB2 frameshift mutations (35delG/167delT) with a documented average threshold decline of 3.71 dB per year over seven years. Following initiation of daily ACEMg, binaural pure-tone average thresholds remained stable over three subsequent years of audiometric follow-up. The transition from documented progressive decline to stability was statistically significant (Fisher's Exact Test, p = 0.044). No adverse effects were observed.

Thatcher A, Le Prell C, Miller J, Green G. ACEMg supplementation ameliorates progressive Connexin 26 hearing loss in a child. Int J Pediatr Otorhinolaryngol. 2014;78(4):564-566.

Read on PubMed

Preclinical Study, 2016

Green and colleagues published preclinical validation using the Gjb2-CKO conditional knockout mouse model. In the post-weaning intervention group, mice receiving an ACEMg diet showed statistically significant ABR threshold improvements exceeding 10 dB at 12 and 16 kHz (p = 0.0026) compared to controls, which continued to deteriorate. Greater inner hair cell preservation was confirmed on histology.

The same study found that ACEMg worsened outcomes in the Diap3-Tg (AUNA1) model, confirming that genetic diagnosis is required before this intervention is considered.

Green KL, Swiderski DL, Prieskorn DM, et al. ACEMg Diet Supplement Modifies Progression of Hereditary Deafness. Sci Rep. 2016;6:22690.

Read Open Access

Real-World Evidence Study in Adults, 2026

A real-world evidence study of ACEMg in 190 adults with sensorineural hearing loss found that 75.3% of ACEMg users maintained or improved hearing over the study period, compared with significant decline in the untreated standard-care group (p < 0.001).

Seifer BS, Minor LA, Detweiler RA. Impact of the ACEMg Biomedicine on Sensorineural Hearing Loss and Auditory Function: Analysis of Real-World Clinical Data. Global Advances in Integrative Medicine and Health. 2026. doi:10.1177/27536130261434488

Submitted: Second Pediatric Case Report, 2026

A case report documenting a second child with confirmed compound heterozygous GJB2 mutations (c.427C>T; c.269T>C) and five-year audiometric progression of 15 to 30 dB has been submitted to Otolaryngology Case Reports. ACEMg supplementation was initiated in March 2026 with prospective audiometric follow-up planned at 6 and 12 months. The case also documents a reproducible pattern of clinical knowledge gaps across audiology, ENT, and genetics providers. Follow-up data will be published as it becomes available.

Research Timeline

1980s
Micronutrient-based hearing preservation research begins at the University of Michigan Kresge Hearing Research Institute under Dr. Josef Miller
2005
Preclinical study demonstrates significant reduction in noise-induced cochlear damage with antioxidant formulation
2007 to 2016
NIH and European Commission fund translational research on ACEMg for noise-induced and ototoxic hearing loss
2014
First published human case report: ACEMg halts GJB2-related progressive hearing loss in a child over three years (Thatcher et al., IJPO)
2016
Preclinical validation in the Gjb2-CKO mouse model; mutation-specific effects confirmed (Green et al., Scientific Reports)
2026
Real-world evidence study in 190 adults with SNHL published (Global Advances in Integrative Medicine and Health)
2026
Second pediatric GJB2 case report submitted; prospective audiometric follow-up ongoing

About GJB2 / Connexin 26 Mutations

GJB2 mutations are the most common cause of hereditary non-syndromic hearing loss, accounting for more than half of all cases of recessive genetic deafness. Carrier rates in the United States exceed 3% of the general population. Although GJB2-related hearing loss is often described as stable, two independent longitudinal studies documented audiometric decline in 24 to 56% of affected children.

Some children pass their newborn hearing screening with near-normal thresholds and experience progressive deterioration over subsequent years, with threshold shifts of 2 to 5 dB per year sustained over years. For these children, no pharmacological or nutritional intervention is currently embedded in standard clinical guidelines.

Genetic diagnostic programs are increasingly integrated into newborn hearing screening infrastructure, enabling earlier identification of the progressive subset. This creates a realistic opportunity for prospective observation of early intervention, at the stage where the preclinical data suggest maximum benefit.

#1Most common cause of hereditary hearing loss

50%+Of non-syndromic hearing loss cases

3%+Carrier rate in the US general population

For Researchers and Clinicians

If you are a pediatric ENT, audiologist, geneticist, or researcher caring for or studying children with GJB2 mutations, we welcome your inquiry. We can provide detailed scientific information, formulation specifications, and the full text of submitted and published manuscripts.

We are specifically interested in connecting with clinicians who are willing to:

Discuss the published ACEMg literature with families of children with confirmed GJB2 mutations and documented audiometric progression
Track audiometric outcomes, ideally including serial otoacoustic emissions (OAE) examinations, in children who elect supplementation
Contribute to a prospective real-world evidence dataset

Email

hello@soundbites.com

Phone

877-439-7722

Please include “GJB2 Clinical Research” in your subject line.

Learn More

How Soundbites Works

Understand the science behind ACEMg and hearing preservation

Patents & IP

View our patent portfolio and intellectual property

Partner With Us

Information for clinicians and healthcare professionals

Soundbites for GJB2 Connexin 26 is available for clinical research and clinical use. It is not available for direct consumer purchase through this channel. The information on this page is intended for healthcare professionals and researchers. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.